ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
55 announcements with these filters
Designated person Rahul Guha bought 2,121 Thyrocare shares via market purchase on November 6, 2026, worth ₹0.10 Crore. Post-trade holding is 200,859 shares.
Thyrocare allotted 1,94,289 equity shares under its Employee Stock Option Scheme. The allotment lifts paid-up capital to Rs 159.36 crore.
Thyrocare Technologies' Chief Scientific Officer, Dr. Preet Kaur, resigns effective November 6, 2026. The company is identifying a replacement and will disclose details later.
Thyrocare disclosed NSE market purchases by an immediate relative and a KMP on 2 November 2026. Combined consideration is about Rs 0.11 Crore, with no promoter involved.
Thyrocare agreed to sell its entire stake in subsidiary Nueclear Healthcare to Trovera. The consideration is about Rs 141.40 Crore, including preference shares and cash.
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.
Thyrocare reports robust 24% growth, pivoting from volume-led routine testing to specialized diagnostics under new management. High operational leverage is evident as PAT growth significantly outpaced revenue.
Q2 FY27 consolidated revenue ₹270.8 Cr (+25.1%), EBITDA ₹89.3 Cr (33.0% margin), PAT before exceptions ₹60.2 Cr (+25.7%). Debt-free; NHL radiology divestment pending.
Thyrocare Technologies reported Q2FY27 consolidated revenue of Rs 270.8 Cr, up 25.1% YoY, with PAT before exceptions of Rs 60.2 Cr. The press release also notes a Rs 45 Cr non-cash NHL impairment tied to a proposed divestment.
Thyrocare Technologies Ltd reported revenue from operations of ₹270.8 Cr (+25.1% YoY) and net profit of ₹15.2 Cr (-68.2% YoY) for Q2 FY27.
Thyrocare Technologies intimated that its Board meeting is scheduled for 29 Oct 2026 to consider Q2/H1 FY27 results. No financial figures or decisions are reported in this prior intimation.
Thyrocare Technologies filed its quarterly shareholding pattern for the period ended September 30, 2026, including a note regarding a prior promoter group amalgamation.
Thyrocare Technologies initiated a postal ballot for two resolutions: purchasing property from its subsidiary, Nueclear Healthcare, and selling its investment in Nueclear Healthcare.
Thyrocare seeks shareholder approval via postal ballot for the purchase of land and building and the divestment of its subsidiary, Nueclear Healthcare Limited.
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
NCLT sanctioned the merger of Docon Technologies into API Holdings. Accordingly, the promoter's 51.02% stake in Thyrocare transfers to API Holdings, leaving the aggregate shareholding unchanged.
Thyrocare Technologies reported the termination of transaction documents and release of a share pledge following the full repayment of Rs.1,700 Crore NCDs by API Holdings.
Thyrocare informed the exchange of the full repayment of NCDs by its holding company API Holdings. Consequently, the share pledge on company equity is released.
ICICI Prudential Mutual Fund sold a 2.06% stake in Thyrocare Technologies through open market transactions. Its holding decreased from 5.33% to 3.27% of the company.
Docon Technologies Private Limited announced the release of a pledge over 1,75,00,000 equity shares of Thyrocare Technologies Ltd. The release occurred on August 11, 2026.
Promoter Docon Technologies sold 1,57,69,696 equity shares of Thyrocare Technologies. Promoter shareholding decreased from 60.92% to 51.02%.
Promoter Docon Technologies Private Limited has released a pledge on 1,75,00,000 equity shares of Thyrocare Technologies Ltd. The pledge was released by Catalyst Trusteeship Limited on August 11, 2026.
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
Thyrocare Technologies submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a machine-readable format as requested by the NSE.
Thyrocare Technologies Limited has re-appointed Ernst & Young LLP as its Internal Auditor for a term of 12 months. This is a routine governance update.
Thyrocare Technologies' Board has approved an in-principle evaluation of a potential demerger or business transfer involving the radiology undertaking of its subsidiary, Nueclear Healthcare Limited.